Vancomycin

Generic Name
Vancomycin
Brand Names
Firvanq, Vancocin
Drug Type
Small Molecule
Chemical Formula
C66H75Cl2N9O24
CAS Number
1404-90-6
Unique Ingredient Identifier
6Q205EH1VU
Background

Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to ristocetin that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.
...

Indication

Administered intravenously, vancomycin is indicated in adult and pediatric patients for the treatment of septicemia, infective endocarditis, skin and skin structure infections, bone infections, and lower respiratory tract infections. Administered orally, vancomycin is indicated in adult and pediatric patients for the treatment of Clostridium difficile-associ...

Associated Conditions
Clostridium Difficile Associated Diarrhea (CDAD), Enterocolitis caused by Staphylococcus aureus, Infection caused by staphylococci, Severe Staphylococcal infection
Associated Therapies
-
Clinical Trials
Related News

Loading Vancomycin Doses in the Emergency Department

Not Applicable
Completed
Conditions
Infectious Disease
Interventions
Drug: Vancomycin
First Posted Date
2010-07-15
Last Posted Date
2014-03-13
Lead Sponsor
Christiana Care Health Services
Target Recruit Count
99
Registration Number
NCT01162733
Locations
🇺🇸

Chrisitana Care Health System-Christiana Hospital, Newark, Delaware, United States

Utility of Vancomycin Loading: A Pharmacokinetic Analysis in Critically Ill Patients

Not Applicable
Terminated
Conditions
Infection
Interventions
Drug: Vancomycin
First Posted Date
2010-07-07
Last Posted Date
2013-03-18
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
1
Registration Number
NCT01157533
Locations
🇺🇸

UT MD Anderson Cancer Center, Houston, Texas, United States

Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens

Phase 4
Terminated
Conditions
Diabetic Foot
Interventions
Drug: Cubicin
Drug: Vancomycin
First Posted Date
2010-05-31
Last Posted Date
2013-09-10
Lead Sponsor
Clinical Alliance for Research & Education - Infectious Diseases, LLC.
Target Recruit Count
6
Registration Number
NCT01133600
Locations
🇺🇸

Clinical Alliance for Research & Education, Infectious Diseases, LlC, Annandale, Virginia, United States

🇺🇸

Infuscience, Annandale, Virginia, United States

Study Comparing the Safety and Efficacy of Two Doses of BC-3781 vs Vancomycin in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Phase 2
Completed
Conditions
Bacterial Infections
Infection
Interventions
Drug: BC-3781
Drug: Vancomycin
First Posted Date
2010-05-07
Last Posted Date
2020-11-17
Lead Sponsor
Nabriva Therapeutics AG
Target Recruit Count
210
Registration Number
NCT01119105
Locations
🇺🇸

BC-3781 Study Center 002, Chula Vista, California, United States

🇺🇸

BC-3781 Study Center 003, Oceanside, California, United States

🇺🇸

BC-3781 Study Center 012, Columbus, Georgia, United States

and more 6 locations

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

First Posted Date
2010-04-15
Last Posted Date
2018-09-05
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
92
Registration Number
NCT01104662

A Pilot Study of Vancomycin or Metronidazole in Patients With Primary Sclerosing Cholangitis

First Posted Date
2010-03-12
Last Posted Date
2013-09-19
Lead Sponsor
Mayo Clinic
Target Recruit Count
35
Registration Number
NCT01085760
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Study of CB-183,315 in Participants With Clostridium Difficile Infection

First Posted Date
2010-03-12
Last Posted Date
2018-09-11
Lead Sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Target Recruit Count
210
Registration Number
NCT01085591
Locations
🇺🇸

Atlanta Institute for Medical Research, Inc, Decatur, Georgia, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

🇺🇸

Gastrointestinal Specialists of Georgia PC, Marietta, Georgia, United States

and more 28 locations

Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections

Not Applicable
Completed
Conditions
Skin and Soft Tissue Infections
Interventions
Drug: vancomycin
First Posted Date
2009-12-22
Last Posted Date
2015-08-27
Lead Sponsor
Fraser Health
Target Recruit Count
4
Registration Number
NCT01037192
Locations
🇨🇦

Royal Columbian Hospital, New Westminster, British Columbia, Canada

Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection

First Posted Date
2009-06-19
Last Posted Date
2015-01-26
Lead Sponsor
Aarhus University Hospital
Registration Number
NCT00925093

Prevention of Neurosurgical Wound Infections

First Posted Date
2009-06-08
Last Posted Date
2019-04-30
Lead Sponsor
Oregon Health and Science University
Target Recruit Count
214
Registration Number
NCT00915967
Locations
🇺🇸

University Hospital, Oregon Health & Science University, Portland, Oregon, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy